MET and familial pancreatic carcinoma: Using both in vivo and in vitro approaches, this study has provided novel evidence to indicate that stromal reprogramming (by inhibiting the HGF/c-MET pathway) combined with chemotherapy significantly reduces pancreatic cancer progression.